Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis
BackgroundCoronavirus disease 2019 (COVID-19) causes life-threatening with the high-fatality rates and spreads with high-infectious disease worldwide. We aimed to systematically review the comorbidities and complications of COVID-19 that are associated with various disease severity, progression, and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.923485/full |
| _version_ | 1828151706881359872 |
|---|---|
| author | Zhe Chen Yingying Peng Yingying Peng Xiaolei Wu Bo Pang Fengwen Yang Wenke Zheng Chunxiang Liu Junhua Zhang |
| author_facet | Zhe Chen Yingying Peng Yingying Peng Xiaolei Wu Bo Pang Fengwen Yang Wenke Zheng Chunxiang Liu Junhua Zhang |
| author_sort | Zhe Chen |
| collection | DOAJ |
| description | BackgroundCoronavirus disease 2019 (COVID-19) causes life-threatening with the high-fatality rates and spreads with high-infectious disease worldwide. We aimed to systematically review the comorbidities and complications of COVID-19 that are associated with various disease severity, progression, and mortality in China, to provide contemporary and reliable estimates in settings with centralized isolation and hospitalization.MethodsIn this systematic review and meta-analysis, we searched four main English language databases, and four main Chinese language databases for observational studies published from inception to January 2022, to identify all the related comorbidities and complications of COVID-19, in the China region with centralized isolation and hospitalization, with disease severity, progression, and mortality. Literature search, data extraction, and quality assessment were independently conducted by two reviewers. We used the generalized linear mixed model to estimate pooled effect sizes for any comorbidities and complications, and subgroup in gender ratio was done to further address the potential heterogeneity.ResultsOverall, 187 studies describing 77,013 patients, namely, 54 different comorbidities and 46 various complications of COVID-19, were identified who met our inclusion criteria. The most prevalent comorbidities were hypertension [20.37% 95% CI (15.28–26.63), 19.29% (16.17–22.85), 34.72% (31.48–38.10), and 43.94% (38.94–49.06)] and diabetes [7.84% (5.78–10.54), 8.59% (7.25–10.16), 17.99% (16.29–19.84), and 22.68% (19.93–25.69)] in mild, moderate, severe, and critical cases. The most prevalent complications were liver injury [10.00% (1.39–46.72), 23.04% (14.20–35.13), and 43.48% (39.88–47.15)] in mild, moderate, and severe cases, and acute respiratory distress syndrome [ARDS; 94.17% (20.78–99.90)] and respiratory failure [90.69% (28.08–99.59)] in critical cases. Renal insufficiency [odds ratio (OR) 17.43 (6.69–45.43)] in comorbidities and respiratory failure [OR 105.12 (49.48–223.33)] in complications were strongly associated in severe/critical than in mild/moderate cases. The highest estimated risk in intensive care unit (ICU) admission, progression, and mortality was an autoimmune disease, nervous system disease, and stroke in comorbidities, shock, and ARDS in complications.ConclusionComorbidities and complications in inpatients with COVID-19 were positively associated with increased risk in severe and critical cases, ICU admission, exacerbation, and death during centralized isolation and hospitalization. Prompt identification of comorbidities and complications in inpatients with COVID-19 can enhance the prevention of disease progression and death and improve the precision of risk predictions. |
| first_indexed | 2024-04-11T22:01:35Z |
| format | Article |
| id | doaj.art-9c70e3eb411549fcaf7a95666597281d |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-11T22:01:35Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-9c70e3eb411549fcaf7a95666597281d2022-12-22T04:00:55ZengFrontiers Media S.A.Frontiers in Public Health2296-25652022-08-011010.3389/fpubh.2022.923485923485Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysisZhe Chen0Yingying Peng1Yingying Peng2Xiaolei Wu3Bo Pang4Fengwen Yang5Wenke Zheng6Chunxiang Liu7Junhua Zhang8Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaBackgroundCoronavirus disease 2019 (COVID-19) causes life-threatening with the high-fatality rates and spreads with high-infectious disease worldwide. We aimed to systematically review the comorbidities and complications of COVID-19 that are associated with various disease severity, progression, and mortality in China, to provide contemporary and reliable estimates in settings with centralized isolation and hospitalization.MethodsIn this systematic review and meta-analysis, we searched four main English language databases, and four main Chinese language databases for observational studies published from inception to January 2022, to identify all the related comorbidities and complications of COVID-19, in the China region with centralized isolation and hospitalization, with disease severity, progression, and mortality. Literature search, data extraction, and quality assessment were independently conducted by two reviewers. We used the generalized linear mixed model to estimate pooled effect sizes for any comorbidities and complications, and subgroup in gender ratio was done to further address the potential heterogeneity.ResultsOverall, 187 studies describing 77,013 patients, namely, 54 different comorbidities and 46 various complications of COVID-19, were identified who met our inclusion criteria. The most prevalent comorbidities were hypertension [20.37% 95% CI (15.28–26.63), 19.29% (16.17–22.85), 34.72% (31.48–38.10), and 43.94% (38.94–49.06)] and diabetes [7.84% (5.78–10.54), 8.59% (7.25–10.16), 17.99% (16.29–19.84), and 22.68% (19.93–25.69)] in mild, moderate, severe, and critical cases. The most prevalent complications were liver injury [10.00% (1.39–46.72), 23.04% (14.20–35.13), and 43.48% (39.88–47.15)] in mild, moderate, and severe cases, and acute respiratory distress syndrome [ARDS; 94.17% (20.78–99.90)] and respiratory failure [90.69% (28.08–99.59)] in critical cases. Renal insufficiency [odds ratio (OR) 17.43 (6.69–45.43)] in comorbidities and respiratory failure [OR 105.12 (49.48–223.33)] in complications were strongly associated in severe/critical than in mild/moderate cases. The highest estimated risk in intensive care unit (ICU) admission, progression, and mortality was an autoimmune disease, nervous system disease, and stroke in comorbidities, shock, and ARDS in complications.ConclusionComorbidities and complications in inpatients with COVID-19 were positively associated with increased risk in severe and critical cases, ICU admission, exacerbation, and death during centralized isolation and hospitalization. Prompt identification of comorbidities and complications in inpatients with COVID-19 can enhance the prevention of disease progression and death and improve the precision of risk predictions.https://www.frontiersin.org/articles/10.3389/fpubh.2022.923485/fullcomorbiditiescomplicationsCOVID-19centralized isolation and hospitalizationsystematic review |
| spellingShingle | Zhe Chen Yingying Peng Yingying Peng Xiaolei Wu Bo Pang Fengwen Yang Wenke Zheng Chunxiang Liu Junhua Zhang Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis Frontiers in Public Health comorbidities complications COVID-19 centralized isolation and hospitalization systematic review |
| title | Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis |
| title_full | Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis |
| title_fullStr | Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis |
| title_full_unstemmed | Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis |
| title_short | Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis |
| title_sort | comorbidities and complications of covid 19 associated with disease severity progression and mortality in china with centralized isolation and hospitalization a systematic review and meta analysis |
| topic | comorbidities complications COVID-19 centralized isolation and hospitalization systematic review |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2022.923485/full |
| work_keys_str_mv | AT zhechen comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT yingyingpeng comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT yingyingpeng comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT xiaoleiwu comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT bopang comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT fengwenyang comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT wenkezheng comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT chunxiangliu comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis AT junhuazhang comorbiditiesandcomplicationsofcovid19associatedwithdiseaseseverityprogressionandmortalityinchinawithcentralizedisolationandhospitalizationasystematicreviewandmetaanalysis |